Weekly update Companies AI-cruiter Recruiting

Casma Therapeutics

Founded: 2017

Location: Cambridge, MA

Employee range: 11 - 50

Clinical stage: RD

Therapy area: Oncology

Drug types: ONC

Lead product: Undisclosed

Product link: https://www.casmatx.com/platform-pipeline/

Funding: $46M C Nov 2022; $50M B Sep 2020; $58.5M A May 2018

Investors: Amgen Ventures, Astellas Venture Management, Eisai Co., Euclidean Capital, Mirae Asset, Ono Venture Investment, Eventide Asset Management, Schroders Capital, The Column Group, Third Rock Ventures

casmatx.com

linkedin.com

job board

Short description:

Autophagy-focused Treatments

Drug notes:

2 additional undisclosed programs RD oncology, inflammation

Long description:

Casma Therapeutics is harnessing the power of autophagy to bring cures to patients with serious diseases. The traditional pharma approach is to use drugs to inhibit the active site of a disease-causing protein. An alternative strategy is to instead destroy the protein entirely. Autophagy is a major cellular degradation pathway that recycles damaged components. Casma’s approach is to boost autophagy and degradation by developing drugs against unique molecular targets generated from their platform. Initially Casma is focusing on new treatments for patients with unmet clinical needs including rare genetic diseases and broader areas such as neurodegeneration, metabolic disorders, and muscle degeneration.

Jobs:

Main

Contact: recruit@workinbiotech.com